Berkshire Bank Sells 774 Shares of Merck & Co., Inc. (NYSE:MRK)

Berkshire Bank decreased its position in Merck & Co., Inc. (NYSE:MRKFree Report) by 1.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 49,621 shares of the company’s stock after selling 774 shares during the period. Merck & Co., Inc. accounts for 1.4% of Berkshire Bank’s portfolio, making the stock its 15th largest position. Berkshire Bank’s holdings in Merck & Co., Inc. were worth $5,410,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. State Street Corp raised its holdings in shares of Merck & Co., Inc. by 1.9% in the second quarter. State Street Corp now owns 118,562,086 shares of the company’s stock valued at $13,766,428,000 after purchasing an additional 2,174,829 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Merck & Co., Inc. by 6.7% during the third quarter. Wellington Management Group LLP now owns 82,442,666 shares of the company’s stock worth $8,487,472,000 after buying an additional 5,196,914 shares in the last quarter. Morgan Stanley increased its holdings in shares of Merck & Co., Inc. by 10.6% during the fourth quarter. Morgan Stanley now owns 41,850,081 shares of the company’s stock worth $4,643,267,000 after purchasing an additional 4,000,816 shares during the period. Moneta Group Investment Advisors LLC lifted its position in shares of Merck & Co., Inc. by 103,159.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 39,327,490 shares of the company’s stock valued at $4,363,385,000 after acquiring an additional 39,289,404 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in Merck & Co., Inc. by 4.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 31,951,714 shares of the company’s stock valued at $3,289,429,000 after buying an additional 1,246,705 shares during the period. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Steven Mizell sold 50,694 shares of the firm’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $126.65, for a total value of $6,420,395.10. Following the transaction, the executive vice president now directly owns 23,619 shares of the company’s stock, valued at $2,991,346.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Merck & Co., Inc. news, insider Joseph Romanelli sold 1,000 shares of the stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total transaction of $124,890.00. Following the completion of the transaction, the insider now directly owns 19,569 shares of the company’s stock, valued at $2,443,972.41. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Steven Mizell sold 50,694 shares of the firm’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $126.65, for a total value of $6,420,395.10. Following the sale, the executive vice president now owns 23,619 shares in the company, valued at approximately $2,991,346.35. The disclosure for this sale can be found here. 0.20% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. StockNews.com raised Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a report on Friday, February 2nd. Barclays upped their price objective on shares of Merck & Co., Inc. from $135.00 to $145.00 and gave the stock an “overweight” rating in a research report on Friday, February 2nd. UBS Group increased their target price on Merck & Co., Inc. from $135.00 to $148.00 and gave the company a “buy” rating in a research report on Friday, February 2nd. Truist Financial restated a “buy” rating and set a $142.00 price target (up from $139.00) on shares of Merck & Co., Inc. in a report on Thursday, March 28th. Finally, TD Cowen upgraded shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $125.00 to $135.00 in a report on Thursday, January 4th. One analyst has rated the stock with a sell rating, four have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $129.71.

Check Out Our Latest Research Report on Merck & Co., Inc.

Merck & Co., Inc. Price Performance

Merck & Co., Inc. stock traded down $0.48 during midday trading on Tuesday, hitting $130.51. 1,957,652 shares of the company’s stock were exchanged, compared to its average volume of 8,641,785. The company has a market cap of $330.53 billion, a P/E ratio of 935.21, a PEG ratio of 0.52 and a beta of 0.38. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.00 and a current ratio of 1.25. The stock has a 50-day moving average price of $125.24 and a two-hundred day moving average price of $113.04. Merck & Co., Inc. has a 52-week low of $99.14 and a 52-week high of $133.10.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its quarterly earnings data on Thursday, February 1st. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.12. The company had revenue of $14.63 billion for the quarter, compared to analysts’ expectations of $14.49 billion. Merck & Co., Inc. had a return on equity of 9.33% and a net margin of 0.61%. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the previous year, the firm posted $1.62 earnings per share. On average, equities research analysts forecast that Merck & Co., Inc. will post 8.59 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 5th. Shareholders of record on Friday, March 15th will be given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 2.36%. The ex-dividend date of this dividend is Thursday, March 14th. Merck & Co., Inc.’s dividend payout ratio is presently 2,200.00%.

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

See Also

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.